NEW YORK, March 19 -- Eurogentec of Sart-Tilman, Belgium, today announced a non-exclusive licensing agreement to manufacture and sell modified oligonucleotides produced with Exiqon's locked nucleic acid technology.
LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products. Eurogentec said in a statement that it plans to use the technology to develop new applications for expression profiling and real-time PCR. The products will be synthesized in Oswell, UK.
Exiqon is based in Copenhagen, Denmark.